多發性骨髓瘤病人臨床成效分析

Clinical Outcomes in Patients with Multiple Myeloma

目的：探討多發性骨髓瘤病人不同治療型態人口學特性與臨床特性對存活率的相關性。方法：以病歷回溯方式收集140名新診斷多發性骨髓瘤病人資料，治療型態分為無接受治療、化學治療合併標靶治療及造血幹細胞移植，以單因子變異數分析比較不同治療型態病人人口學及臨床特性與存活，Kaplan-Meier及Cox迴歸分析存活風險影響因子。結果：本研究共140名新診斷多發性骨髓瘤病人納入研究，平均年齡為64.89歲，男性80人、女性60人，89.29%的病人會接受治療，人口學特性與臨床特性對存活率有顯著差異，病人的年齡大於70歲死亡率最高，治療方式以造血幹細胞移植存活時間(p<0.001)最長。結論：隨著人口的高齡化，罹病人數逐漸增加，因疾病初期無明顯症狀，導致治療延誤，進而影響病人的存活率，並對醫療資源的利用造成影響。

Objective: To investigate the correlation between demographic and clinical characteristics, treatment modalities, and survival outcomes in patients with multiple myeloma (MM). Methods: Data were retrospectively collected from 140 patients with newly diagnosed MM. Treatment modalities were classified as no treatment, chemotherapy with targeted therapy, and hematopoietic stem cell transplantation (HSCT). One-way analysis of variance was used to compare demographic and clinical characteristics and survival across treatment groups. Survival risk factors were analyzed using Kaplan–Meier and Cox regression models. Results: A total of 140 patients with newly diagnosed MM were included in the study, with a mean age of 64.89 years. Of them, 80 were men, and 60 were women. In this sample, 89.29% received treatment. Survival rates significantly varied with demographic and clinical characteristics. Patients aged >70 years had the highest mortality. HSCT was associated with the longest survival (p < 0.001). Conclusion: MM is becoming more common as populations age. Due to the disease’s asymptomatic early stages, delayed diagnosis and treatment are common, adversely affecting survival outcomes and the health-care resources.